Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transcode Therapeutics Inc (NQ: RNAZ )

0.5899 +0.0029 (+0.49%)
Streaming Delayed Price Updated: 1:06 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Transcode Therapeutics Inc

< Previous 1 2 3 Next >
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
Highlights TTX-MC138’s Path from Target Discovery to the Clinic 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Withdraws Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
Suggests potential to improve survival outcomes in patients with GBM 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
Evidence of Drug Accumulation in Metastatic Lesions 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
Study showed a 70% Inhibition of Recurrent Tumor Growth 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
Designed to demonstrate delivery of TTX-MC138 to metastatic lesions 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.